Business
ENvue Medical, Formerly NanoVibronix, UroShield® Kit Secures Reimbursement in the UK
Peak Medical, ENvue’s Exclusive Distributor in UK, Places Significant Order after Reimbursement Decision, Projecting Future Market Demand for UroShield® KitTYLER, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (NASDAQ: NAOV) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that the UroShield® Kit has been added to the UK National Health Service (NHS) Drug Tariff Part IX, enabli
About this update from Envue Medical, Inc.
[{"type":"image","alt":"ENvue Medical, Inc.","displaySize":"","headline":null,"caption":"ENvue Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/e735564e4b61ea457ed5c24973dfd284"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jnXolgcAdzqINbRTdJetTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e735564e4b61ea457ed5c24973dfd284","width":300,"height":79}},"lazy":false},{"type":"text","content":"Peak Medical, ENvue’s Exclusive Distributor in UK, Places Significant Order after Reimbursement Decision, Projecting Future Market Demand for UroShield® Kit","length":156,"tagName":"p"},{"type":"text","content":"TYLER, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (NASDAQ: NAOV) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that the UroShield® Kit has been added to the UK National Health Service (NHS) Drug Tariff Part IX, enabling nationwide prescription reimbursement across the UK.","length":404,"tagName":"p"},{"type":"text","content":"In parallel with this reimbursement milestone, ENvue Medical has secured an initial purchase order from Peak Medical, a leading UK-based distributor specializing in stoma care and urology medical devices with a vast network of hospitals and community settings, reflecting early commercial demand following NHS Drug Tariff inclusion.","length":332,"tagName":"p"},{"type":"text","content":"The NHS Drug Tariff Part IX establishes a direct, prescription-based reimbursement pathway, significantly expanding access for the UroShield® Kit, which is used in conjunction with the UroShield® Actuator that was previously included in the NHS Drug Tariff Part IX in the UK in 2023, across community and hospital care settings. Long-term urinary catheterization is common in the UK, with published studies indicating catheter prevalence of approximately 6–7% in long-term care populations, a patient group associated with elevated risk of catheter-associated urinary tract infections (CAUTIs).¹","length":595,"tagName":"p"},{"type":"text","content":"UroShield® is a non-invasive device designed to reduce catheter-associated urinary tract infections (CAUTIs) and catheter blockages...